These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Phase II trial of vaginal cuff brachytherapy followed by dose-dense chemotherapy in early stage endometrial cancer patients with enriched, high-intermediate risk factors for recurrence. Castellano T; John Maxwell IV; Adam Walter J; Thompson S; McMeekin DS; Landrum LM Gynecol Oncol; 2021 Mar; 160(3):669-673. PubMed ID: 33358492 [TBL] [Abstract][Full Text] [Related]
28. Salvage high-dose-rate brachytherapy and external beam radiotherapy for isolated vaginal recurrences of endometrial cancer with no prior adjuvant therapy. Chapman CH; Maghsoudi K; Littell RD; Chen LM; Hsu IC Brachytherapy; 2017; 16(6):1152-1158. PubMed ID: 28802913 [TBL] [Abstract][Full Text] [Related]
29. Dynamics of High Risk Clinical Target Volume reduction during Brachytherapy and impact on its coverage in patients with inoperable cervical cancer. Pobijakova M; Scepanovic D; Paluga M; Fekete M; Mardiak J Neoplasma; 2018 Mar; 65(3):425-430. PubMed ID: 29788726 [TBL] [Abstract][Full Text] [Related]
30. Dosimetric impact of bladder filling on organs at risk with barium contrast in the small bowel for adjuvant vaginal cuff brachytherapy. Buzón MDCS; Bayard LG; Sanchez RR; Rodríguez LÁQ; Gil SS; Higueras CM J Contemp Brachytherapy; 2021 Dec; 13(6):655-662. PubMed ID: 35079252 [TBL] [Abstract][Full Text] [Related]
32. Body Mass Index and Doses at Organs at Risk in a Mediterranean Population Treated with Postoperative Vaginal Cuff Brachytherapy. Sabater S; Arenas M; Berenguer R; Andres I; Jimenez-Jimenez E; Martos A; Fernandez-Lopez J; Sevillano M; Rovirosa A Cancer Res Treat; 2015 Jul; 47(3):473-9. PubMed ID: 25672575 [TBL] [Abstract][Full Text] [Related]
33. Bladder distension improves the dosimetry of organs at risk during intracavitary cervical high-dose-rate brachytherapy. Harmon G; Chinsky B; Surucu M; Harkenrider M; Small W Brachytherapy; 2016; 15(1):30-4. PubMed ID: 26521661 [TBL] [Abstract][Full Text] [Related]
34. EROS 2.0 study: evaluation of two interventional radiotherapy (brachytherapy) schedules for endometrial cancer: a comparison of late vaginal toxicity rates. Lancellotta V; Macchia G; Dinapoli N; Autorino R; Campitelli M; Nardangeli A; Salvati A; Fionda B; Casà C; Cornacchione P; Rovirosa A; Kovács G; Morganti AG; Ferrandina MG; Gambacorta MA; Tagliaferri L Radiol Med; 2022 Mar; 127(3):341-348. PubMed ID: 35092552 [TBL] [Abstract][Full Text] [Related]
35. Adjuvant Pelvic Radiation Therapy±Vaginal Brachytherapy in Patients With High-risk Stage I or Stage II Uterine Papillary Serous, Clear Cell, and High-grade Endometrioid Carcinoma. Nagar H; Yan W; Parashar B; Nori D; Chao KS; Christos P; Gupta D; Holcomb K; Caputo T; Wernicke AG Am J Clin Oncol; 2016 Aug; 39(4):335-9. PubMed ID: 27028349 [TBL] [Abstract][Full Text] [Related]
36. Overview of adjuvant radiotherapy on survival, failure pattern and toxicity in stage I to II endometrial carcinoma: a long-term multi-institutional analysis in China. Wang W; Wang T; Liu Z; He J; Sun X; Zhong W; Zhao F; Li X; Li S; Zhu H; Ma Z; Hu K; Zhang F; Hou X; Wei L; Zou L BMC Cancer; 2022 Mar; 22(1):266. PubMed ID: 35287626 [TBL] [Abstract][Full Text] [Related]
37. Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics. Young MR; Higgins SA; Ratner E; Yu JB; Mani S; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Damast S Int J Gynecol Cancer; 2015 Mar; 25(3):431-9. PubMed ID: 25621409 [TBL] [Abstract][Full Text] [Related]
38. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation. Jolly S; Vargas CE; Kumar T; Weiner SA; Brabbins DS; Chen PY; Floyd W; Martinez AA Gynecol Oncol; 2006 Oct; 103(1):87-93. PubMed ID: 16545441 [TBL] [Abstract][Full Text] [Related]
39. Inter-application displacement of brachytherapy dose received by the bladder and rectum of the patients with inoperable cervical cancer. Marosevic G; Ljuca D; Osmic H; Fazlic S; Arsovski O; Mileusnic D Radiol Oncol; 2014 Jun; 48(2):203-9. PubMed ID: 24991211 [TBL] [Abstract][Full Text] [Related]
40. Dosimetric comparison of brachytherapy sources for high-dose-rate treatment of endometrial cancer: (192)Ir, (60)Co and an electronic brachytherapy source. Mobit PN; Nguyen A; Packianathan S; He R; Yang CC Br J Radiol; 2016; 89(1059):20150449. PubMed ID: 26743941 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]